이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Baudax Bio 대차 대조표 상태

재무 상태 기준 확인 0/6

Baudax Bio 의 총 주주 지분은 $-1.2M 이고 총 부채는 $5.2M, 이는 부채 대 자기자본 비율을 -436.4% 로 가져옵니다. 총자산과 총부채는 각각 $20.6M 및 $21.8M 입니다.

주요 정보

-436.4%

부채 비율

US$5.23m

부채

이자 보상 비율	n/a
현금	US$363.00k
주식	-US$1.20m
총 부채	US$21.78m
총 자산	US$20.58m

최근 재무 상태 업데이트

Recent updates

Baudax Bio's Anjeso shows efficacy in pain management for total knee arthroplasty

Apr 26

Have Insiders Been Buying Baudax Bio, Inc. (NASDAQ:BXRX) Shares?

Feb 17

Baudax Bio EPS of $0.62

Nov 09

Baudax Bio: Why I'm Catching This Falling Knife

Nov 03

재무 상태 분석

단기부채: BXRX.Q 에는 음의 주주 지분이 있는데, 이는 단기 부채를 감당하지 못하는 단기 자산보다 더 심각한 상황입니다.

장기 부채: BXRX.Q 의 주주 지분은 음수입니다. 이는 장기 부채를 감당하지 못하는 단기 자산보다 더 심각한 상황입니다.

부채 대 자본 내역 및 분석

부채 수준: BXRX.Q 은 부정주주자본을 갖고 있는데, 이는 높은 부채 수준보다 더 심각한 상황입니다.

부채 감소: BXRX.Q 의 주주 지분은 음수이므로 시간이 지남에 따라 부채가 감소했는지 확인할 필요가 없습니다.

대차 대조표

현금 런웨이 분석

과거에 평균적으로 적자를 기록했던 기업의 경우, 최소 1년 이상의 현금 유동성을 보유하고 있는지 평가합니다.

안정적인 현금 활주로: BXRX.Q 의 현재 여유 현금 흐름을 기준으로 충분한 현금 활주로가 있는지 판단하기에는 데이터가 부족합니다.

예측 현금 활주로: BXRX.Q 의 여유 현금 흐름이 역사적 비율에 따라 계속 증가하거나 감소하는 경우 충분한 현금 활주로가 있는지 판단하기에는 데이터가 부족합니다.

Baudax Bio 대차 대조표 상태

재무 상태 기준 확인 0/6

주요 정보

최근 재무 상태 업데이트

First Motion for Exclusivity Period Extension Approved For Baudax Bio, Inc.

First Motion for Exclusivity Period Extension Filed by Baudax Bio, Inc.

Baudax Bio, Inc. Filed for Bankruptcy

The Nasdaq Stock Market to Delist the Common Stock of Baudax Bio

Nasdaq Hearings Panel Determines to Delist the Baudax Bio's Common Stock from Nasdaq Capital Market

Baudax Bio, Inc. announced delayed 10-Q filing

Recent updates

First Motion for Exclusivity Period Extension Approved For Baudax Bio, Inc.

First Motion for Exclusivity Period Extension Filed by Baudax Bio, Inc.

Baudax Bio, Inc. Filed for Bankruptcy

The Nasdaq Stock Market to Delist the Common Stock of Baudax Bio

Baudax Bio, Inc.(OTCPK:BXRX) dropped from NASDAQ Composite Index

Nasdaq Hearings Panel Determines to Delist the Baudax Bio's Common Stock from Nasdaq Capital Market

Baudax Bio, Inc. to Initiate TI-168 Clinical Development

Baudax Bio, Inc. has completed a Follow-on Equity Offering.

Baudax Bio, Inc. announced delayed 10-Q filing

Baudax Bio, Inc. Appoints Yong Chan Kim as A Member of the Board

Baudax Bio Receives Deficiency Letter from Nasdaq Regarding Non-Compliance with Nasdaq Minimum Bid Price Requirement

Baudax Bio Receives A Delist Determination Letter from Nasdaq Stock Market LLC Advising the Company Not Meeting the Terms of Extension

Baudax Bio, Inc. Announces Positive Outcome of Interim Analysis of Phase Ii Randomized Trial for B1000

Baudax Bio Initiates Phase II Clinical Trial Evaluating BX1000 in Patients Undergoing Surgery

Baudax Bio, Inc. has completed a Follow-on Equity Offering.

Baudax Bio Receives Non Compliance Letter from Nasdaq

Baudax Bio, Inc. Reports Impairment Charges for the Third Quarter Ended September 30, 2022

Baudax Bio, Inc. has completed a Follow-on Equity Offering in the amount of $6.205065 million.

Baudax Bio stock down after pricing $6.2M equity offering

Baudax Bio to get US patent linked to pain drug Anjeso

Baudax Bio GAAP EPS of -$1.05 beats by $0.22, revenue of $0.3M

Baudax Bio Receives Deficiency Letter from Nasdaq

Cosette Pharmaceuticals appoints Rick Casten as CFO

Baudax Bio Announces Dosing of First Cohort in First-in-Man, Phase I Clinical Study Evaluating BX2000

Baudax Bio, Inc. to Report Q1, 2022 Results on May 05, 2022

Baudax Bio, Inc., Annual General Meeting, May 04, 2022

Baudax Bio, Inc. Initiates Phase IV Clinical Trial Evaluating ANJESO® in Pediatric Patients Following Surgery

Baudax Bio, Inc. has completed a Follow-on Equity Offering in the amount of $10 million.

Baudax Bio, Inc. has completed a Follow-on Equity Offering in the amount of $10 million.

Baudax Bio Announces 1-For-35 Reverse Stock Split

Third quarter 2021 earnings released: US$0.20 loss per share (vs US$0.64 profit in 3Q 2020)

Baudax Bio: Looking For A Turnaround In Strong COVID-19 Headwinds

Independent Director recently bought US$63k worth of stock

Consensus forecasts updated

Baudax Bio, Inc.(NasdaqCM:BXRX) dropped from Russell Microcap Value Index

Baudax Bio Receives A Deficiency Letter from the Nasdaq Listing Qualifications Department

A First Look At Baudax Bio

Baudax Bio Announces Publication of Phase IIIb ANJESO® Data in the Journal Pain Management

Consensus revenue estimates fall to US$3.50m

Baudax Bio EPS misses by $0.08, misses on revenue

Baudax Bio, Inc. Announces Publication of Phase IIIb Data on Preoperative Administration of Anjeso in Patients Undergoing Total Knee Arthroplasty in Pain Medicine

Baudax Bio's Anjeso shows efficacy in pain management for total knee arthroplasty

Baudax Bio, Inc., Annual General Meeting, Apr 07, 2021

Baudax Bio Strengthens Management Team with Appointment of Richard S. Casten as Chief Financial Officer

Revenue and earnings miss expectations

Have Insiders Been Buying Baudax Bio, Inc. (NASDAQ:BXRX) Shares?

Price target lowered to US$8.00

Analysts update estimates

Baudax Bio, Inc. to Report Q4, 2020 Results on Feb 16, 2021

New 90-day high: US$1.94

Baudax Bio, Inc.(NasdaqCM:BXRX) dropped from Russell 2000 Dynamic Index

New 90-day high: US$1.70

New 90-day low: US$0.99

Baudax Bio Announces Publication of Anjeso Network Meta-Analysis in the Peer-Reviewed Journal Bmc Anesthesiology

New 90-day low: US$1.00

Earnings beat expectations, revenue disappoints

Baudax Bio EPS of $0.62

Baudax Bio, Inc. to Report Q3, 2020 Results on Nov 09, 2020

Baudax Bio: Why I'm Catching This Falling Knife

Analysts update estimates

New 90-day low: US$1.58

Baudax Bio, Inc.(NasdaqCM:BXRX) dropped from S&P Global BMI Index

Analysts update estimates

New 90-day low - US$2.76

Baudax Bio, Inc. to Report Q2, 2020 Results on Aug 10, 2020

Baudax Bio, Inc.(NasdaqCM:BXRX) dropped from Russell 3000 Index

Baudax Bio, Inc.(NasdaqCM:BXRX) dropped from Russell 2000 Dynamic Index

Baudax Bio, Inc.(NasdaqCM:BXRX) dropped from Russell 2500 Growth Index

Baudax Bio, Inc.(NasdaqCM:BXRX) dropped from Russell 2000 Index